Találati lista | Tudóstér

001-es BibID:	BIBFORM083082
035-os BibID:	(PMID)31945149 (WoS)000523314100008 (Scopus)85081944235
Első szerző:	Straus, David J.
Cím:	Brentuximab vedotin with chemotherapy for Stage III/IV classical Hodgkin lymphoma : 3-year update of the ECHELON-1 study / David J. Straus, Monika Długosz-Danecka, Sergiy Alekseev, Árpád Illés, Marco Picardi, Ewa Lech-Maranda, Tatyana Feldman, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Jan Walewski, Radhakrsihnan Ramchandren, Pier Luigi Zinzani, Martin Hutchings, Joseph M. Connors, John Radford, Javier Munoz, Won Seog Kim, Ranjana Advani, Stephen Ansell, Anas Younes, Harry Miao, Rachael Liu, Keenan Fenton, Andres Forero-Torres, Andrea Gallamini
Dátum:	2020
Megjegyzések:	The phase 3 ECHELON-1 study demonstrated that brentuximab vedotin (A) with AVD (A+AVD) exhibited superior modified PFS versus ABVD for the frontline treatment of patients with stage III/IV classical Hodgkin lymphoma (cHL) (NCT01712490; 2011-005450-60). Maturing data from positron emission tomography (PET)-adapted trials highlight potential limitations of PET-adapted approaches, including toxicities with dose intensification and higher-than-expected relapse rates in PET2(-) patients. We present here an update of the ECHELON-1 study, including an exploratory analysis of 3-year PFS per investigator. 1334 patients with stage III or IV cHL were randomized 1:1 to receive six cycles of A+AVD (n = 664) or ABVD (n = 670). Interim PET scan after cycle 2 (PET2) was required. At a median follow-up of 37 months, 3-year PFS rates were 83.1% with A+AVD and 76.0% with ABVD; 3-year PFS rates in PET2(-) patients aged <60 years were 87.2% versus 81.0%, respectively. A beneficial trend in PET2(+) patients aged <60 years on A+AVD was also observed, with a 3-year PFS rate of 69.2% versus 54.7% with ABVD. The benefit of A+AVD in the intent-to-treat population appeared independent of disease stage and prognostic risk factors. Upon continued follow-up, 78% of patients with peripheral neuropathy (PN) on A+AVD had either complete resolution or improvement compared with 83% on ABVD. These data highlight that A+AVD provides a durable efficacy benefit compared with ABVD for frontline stage III/IV cHL which is consistent across key subgroups regardless of patient status at PET2, without need for treatment intensification or exposure to bleomycin.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Blood. - 135 : 10 (2020), p. 735-742. -
További szerzők:	Długosz-Danecka, Monika Alekseev, Sergey Illés Árpád (1959-) (belgyógyász, haematológus, onkológus) Picardi, Marco Lech-Maranda, Ewa Feldman, Tatyana Smolewski, Piotr Savage, Kerry J. Bartlett, Nancy L. Walewski, Jan Ramchandren, Radhakrishnan Zinzani, Pier Luigi Hutchings, Martin Connors, Joseph M. Radford, John Munoz, Javier Kim, Won Seog Advani, Ranjana Ansell, Stephen M. Younes, Anas Miao, Harry Liu, Rachael Fenton, Keenan Forero-Torres, Andres Gallamini, Andrea
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon: